Novo makes a gene editing move

After a couple of recent big acquisitions, Novo Nordisk has gone back to what it knows best: collaborations over intriguing but early technology. Today’s partner is Life Edit Therapeutics, and the technology is gene editing – a hot sector that Novo has previously bet against.